Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology

Giuseppe Patti, the Italian Study Group on Atherosclerosis, Thrombosis, Vascular Biology, Veronica Lio, Ilaria Cavallari, Felice Gragnano, Letizia Riva, Paolo Calabrò, Giuseppe Di Pasquale, Vittorio Pengo, Andrea Rubboli
2020 American Journal of Cardiovascular Drugs  
In patients with coronavirus disease 2019 (COVID-19), the prevalence of pre-existing cardiovascular diseases is elevated. Moreover, various features, also including pro-thrombotic status, further predispose these patients to increased risk of ischemic cardiovascular events. Thus, the identification of optimal antithrombotic strategies in terms of the risk-benefit ratio and outcome improvement in this setting is crucial. However, debated issues on antithrombotic therapies in patients with
more » ... 9 are multiple and relevant. In this article, we provide ten questions and answers on risk stratification and antiplatelet/anticoagulant treatments in patients at risk of/with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on the scientific evidence gathered during the pandemic.
doi:10.1007/s40256-020-00446-6 pmid:33145698 fatcat:ekkvgy2ajzcqnm6cj3knerhdxm